• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • WORLD EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • WORLD EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    Canna-V-Cell Sciences Inc., Announces Significant Milestone

    Nataly Cure
    Aug. 26, 2019 06:12AM PST
    Cannabis Investing News
    CSE:CNVC

    Canna-V-Cell Sciences Inc.  (CSE:CNVC) (“CannaVcell”)announces today it has reached a significant milestone of having Cannabis trichomes at the suspension phase.

    Canna-V-Cell Sciences Inc.  (CSE:CNVC) (“CannaVcell”)announces today it has reached a significant milestone of having Cannabis trichomes at the suspension phase. “This clearly confirms that the progress made to-date towards the completion of the 16 months development program has exceeded the expectations” said Dr. Yochi Hagay CTO of CannaVcell and added ” we can now be assured that the goals of the program will be achieved ahead of schedule”.

    Figure 1: Picture of Trichomes grown in suspension using Biofarming

    To view an enhanced version of Figure 1, please visit:
    https://orders.newsfilecorp.com/files/6168/47264_1edf625bf4c6890a_002full.jpg

    Figure 2: Trichomes grown on Cannabis

    To view an enhanced version of Figure 2, please visit:
    https://orders.newsfilecorp.com/files/6168/47264_1edf625bf4c6890a_003full.jpg

    As of October 2018, CannaVcell has embarked on a 16 months program to prove the feasibility of applying its unique Biofarming technology on Cannabis. Biofarming Cannabis represents a revolution in producing the Cannabis active ingredients also known as Cannabinoids without growing the plant itself.

    “We are excited about this latest achievement. It means we will be able to start diverting more resources (stemming from the current private placement) towards the manufacturing phase.” said Dr. Zaki Rakib, CEO of CannaVcell and added “Biofarming is the only NON GMO Natural Biosynthesis technology available today that can economically produce single cannabinoids and/or their entire entourage.”

    About Canna-V-Cell Sciences Inc.

    Based in Vancouver BC, Canna-V-Cell Sciences Inc. (CNVC) is the exclusive Cannabis worldwide licensee of the proprietary and patent protected BioHarvest technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. By adopting this technology and building adequate cells production capacity, Canna-V-Cell’s objective is to become the leading supplier of Cannabis for both the medicinal and recreational legal use.

    Canna-V-Cell Sciences Inc.

    Dr. Zaki Rakib
    Founder & CEO

    For further information, please contact:
    Email: inquiries@cannavcellsciences.ca
    Local Phone: 604.373.4774
    Toll Free: 833.727.4774

    Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things, risks and uncertainties relating to the fact that the Company would require additional funds in order to construct a commercial biochamber facility and risks related to the adaption of the BioHarvest technology to cannabis. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

    Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

    Click here to connect with Canna-V-Cell Sciences Inc. (CSE:CNVC) for an Investor Presentation.

    Source: www.newsfilecorp.com

    canna-v-cell sciences inc.cannabis investingcse:cnvcbioharvest technology
    The Conversation (0)

    Go Deeper

    AI Powered

    Toxic Spill at Grupo Mexico Mine Turns Rivers Orange

    bctx stock

    BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×